Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 40, 2018, Pages E9381-E9390

  Taracanova, Alexandra ^a   Tsilioni, Irene ^a   Conti, Pio ^b   Norwitz, Errol R ^a   Leeman, Susan E ^c   Theoharides, Theoharis C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 1 ; IL 33; Inflammation; Mast cells; Substance P

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CASPASE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 33; LUTEOLIN; METHOXYLUTEOLIN; PROCASPASE 1; RECEPTOR ANTIBODY; SUBSTANCE P; UNCLASSIFIED DRUG; 3-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYLOXY)-2-PHENYLPIPERIDINE; BIPHENYL DERIVATIVE; IL1B PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1BETA CONVERTING ENZYME; PIPERIDINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LEVEL; CELLULAR SECRETION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LAD 2 CELL LINE; MAST CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RNA ISOLATION; UMBILICAL CORD BLOOD CELL; UPREGULATION; CYTOLOGY; METABOLISM; SECRETION (PROCESS); TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CASPASE 1; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-33; LUTEOLIN; MAST CELLS; PIPERIDINES; SUBSTANCE P;

EID: 85054381724     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1810133115     Document Type: Article

References (70)

1. Rodewald HR, Dessing M, Dvorak AM, Galli SJ (1996) Identification of a committed precursor for the mast cell lineage. Science 271:818–822.
2. Kitamura Y, Ito A (2005) Mast cell-committed progenitors. Proc Natl Acad Sci USA 102: 11129–11130.
3. Schmetzer O, Valentin P, Church MK, Maurer M, Siebenhaar F (2016) Murine and human mast cell progenitors. Eur J Pharmacol 778:2–10.
4. Galli SJ, Tsai M (2010) Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 40:1843–1851.
5. Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163–172.
6. Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454:445–454.
7. Bachelet I, Levi-Schaffer F, Mekori YA (2006) Mast cells: Not only in allergy. Immunol Allergy Clin North Am 26:407–425.
8. Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18:693–704.
9. Rivera J, Fierro NA, Olivera A, Suzuki R (2008) New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 98:85–120.
10. Church MK, el-Lati S, Caulfield JP (1991) Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 94:310–318.
11. Theoharides TC, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107: 4448–4453.
12. Taracanova A, et al. (2017) SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci USA 114:E4002–E4009.
13. Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypo-thalamic tissue and its characterization as substance P. J Biol Chem 245:4784–4790.
14. Mashaghi A, et al. (2016) Neuropeptide substance P and the immune response. Cell Mol Life Sci 73:4249–4264.
15. O’Connor TM, et al. (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167–180.
16. Hökfelt T, Pernow B, Wahren J (2001) Substance P: A pioneer amongst Neuropeptides. J Intern Med 249:27–40.
17. Douglas SD, Leeman SE (2011) Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci 1217:83–95.
18. Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346:274–276.
19. Cao J, Cetrulo CL, Theoharides TC (2006) Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 69: 998–1006.
20. Artuc M, Hermes B, Steckelings UM, Grützkau A, Henz BM (1999) Mast cells and their mediators in cutaneous wound healing–Active participants or innocent bystanders? Exp Dermatol 8:1–16.
21. Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F (2005) Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 116:531–536.
22. Theoharides TC, et al. (2012) Mast cells and inflammation. Biochim Biophys Acta 1822: 21–33.
23. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: Back to the future. Immunity 39:1003–1018.
24. Moulin D, et al. (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40:216–225.
25. Saluja R, et al. (2015) The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 63:80–85.
26. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P (2015) Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 354:24–31.
27. Theoharides TC (2016) Danger signals and inflammation. Clin Ther 38:996–999.
28. Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 10:103–110.
29. Silver MR, et al. (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59:207–218.
30. Halova I, et al. (2018) Changing the threshold–Signals and mechanisms of mast cell priming. Immunol Rev 282:73–86.
31. Weng Z, Patel AB, Panagiotidou S, Theoharides TC (2015) The novel flavone tetra-methoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 135: 1044–52.e5.
32. Patel AB, Theoharides TC (2017) Methoxyluteolin inhibits Neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J Pharmacol Exp Ther 361:462–471.
33. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550.
34. Latz E (2010) The inflammasomes: Mechanisms of activation and function. Curr Opin Immunol 22:28–33.
35. Vanaja SK, Rathinam VA, Fitzgerald KA (2015) Mechanisms of inflammasome activation: Recent advances and novel insights. Trends Cell Biol 25:308–315.
36. Lamkanfi M, et al. (2009) Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol 187:61–70.
37. Babina M, et al. (2004) Comparative cytokine profile of human skin mast cells from two compartments–Strong resemblance with monocytes at baseline but induction of IL-5 by IL-4 priming. J Leukoc Biol 75:244–252.
38. Jeon IH, et al. (2014) Anti-inflammatory and antipruritic effects of luteolin from Pe-rilla (P. frutescens L.) leaves. Molecules 19:6941–6951.
39. Okamura Y, et al. (2017) The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis. Allergol Int 66S:S9–S20.
40. Dowling JK, O’Neill LA (2012) Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 47:424–443.
41. Lu A, Wu H (2015) Structural mechanisms of inflammasome assembly. FEBS J 282: 435–444.
42. Schroder K, Zhou R, Tschopp J (2010) The NLRP3 inflammasome: A sensor for metabolic danger? Science 327:296–300.
43. Jo EK, Kim JK, Shin DM, Sasakawa C (2016) Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13:148–159.
44. Franchi L, Núñez G (2012) Immunology. Orchestrating inflammasomes. Science 337: 1299–1300.
45. Dinarello CA (2003) Setting the cytokine trap for autoimmunity. Nat Med 9:20–22.
46. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652.
47. Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20–38.
48. Robuffo I, et al. (2017) Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL-1 family members. J Biol Regul Homeost Agents 31:837–842.
49. Kim SR, et al. (2014) NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis 5:e1498.
50. Ruscitti P, et al. (2015) Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: A possible implication for therapeutic decision in these patients. Clin Exp Immunol 182:35–44.
51. Inoue M, Shinohara ML (2013) NLRP3 inflammasome and MS/EAE. Autoimmune Dis 2013:859145.
52. Nakamura Y, et al. (2012) Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 37: 85–95.
53. Carlström M, Ekman AK, Petersson S, Söderkvist P, Enerbäck C (2012) Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol 21: 932–937.
54. Johnston A, et al. (2017) IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol 140:109–120.
55. Johansen C, Moeller K, Kragballe K, Iversen L (2007) The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 127:2857–2864.
56. Niebuhr M, Baumert K, Heratizadeh A, Satzger I, Werfel T (2014) Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu. Allergy 69:1058–1067.
57. Dubois EA, Rissmann R, Cohen AF (2011) Rilonacept and canakinumab. Br J Clin Pharmacol 71:639–641.
58. Ruzicka T, Mihara R (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:2093.
59. Finn DF, Walsh JJ (2013) Twenty-first century mast cell stabilizers. Br J Pharmacol 170: 23–37.
60. Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M (2018) Mast cells as drivers of disease and therapeutic targets. Trends Immunol 39:151–162.
61. Weng Z, et al. (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PloS One 7:e33805.
62. Vieira Dos SR, et al. (2010) Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 162:674–676.
63. Notas G, et al. (2012) Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. J Nutr Biochem 23:656–666.
64. Yang Y, et al. (2013) Polyphenols differentially inhibit degranulation of distinct subsets of vesicles in mast cells by specific interaction with granule-type-dependent SNARE complexes. Biochem J 450:537–546.
65. Cao J, Zhang Y, Chen W, Zhao X (2010) The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. Br J Nutr 103: 249–255.
66. Kirshenbaum AS, et al. (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27:677–682.
67. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC (2012) Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 7:e49767.
68. Guhl S, Babina M, Neou A, Zuberbier T, Artuc M (2010) Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells–Drastically reduced levels of tryptase and chymase in mast cell lines. Exp Dermatol 19:845–847.
69. Zhang B, et al. (2011) Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. J Allergy Clin Immunol 127:1522–31.e8.
70. Theoharides TC (2016) Skin mast cells: Are we missing the forest for the trees? Exp Dermatol 25:422–423.